No cydy will never go bankrupt. The biotech companies that go babkrupt are the ones that have a single use drug that is determined ineffective or unsafe. Leronlimab will never ever fall into that category. My opinion is that many including myself will continue to add at these prices and management will focus resources on getting first approval and major partnerships. If you look at volume even on bad news day like clinical trial hold only about 3% of float traded. 97%+ held strong and many of that 3% was shorts and flippers. CYDY still has all the prospects for major big pharma at a severely discounted sp currently.